PeptidePedia The community reference

Talk:Glucagon-like peptide-1

Discussion page·5 threads·2 archives

This article is within the scope of the pharmacology working group, which aims to improve coverage of receptor pharmacology on PeptidePedia.
Rated B-class on the assessment scale. Comments on what is missing for A-class are welcome below.

This is the discussion page for the article Glucagon-like peptide-1. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Readability of the signalling section

Tagged {{technical}}. The signalling paragraph currently expects the reader to already know what a class B GPCR is. The article should be readable by someone who has arrived here from a news story about weight-loss drugs, at least as far as the end of the lead and §Physiological actions.

I am not proposing we remove the pharmacology — just that the first mention of Gs coupling should be glossed in plain language. — — Ref_Desk_Ron (talk) 10:31, 8 March 2026 (UTC)

Reasonable. The figure caption does some of that work already. Suggest: "couples to the stimulatory G protein Gs, raising intracellular cyclic AMP" on first mention, and leave the detail to GLP-1 receptor. — — ReceptorRhoda (talk) 14:52, 8 March 2026 (UTC)

That would satisfy me. Leaving the tag until someone makes the edit. — — Ref_Desk_Ron (talk) 08:15, 9 March 2026 (UTC)

As a recent arrival to the topic: the part I could not follow was not the G protein, it was "glucose-dependent". It took me three readings to understand that means the hormone only pushes insulin when glucose is high. A parenthetical would have saved me. — — NewLabNell (talk) 19:06, 2 April 2026 (UTC)

That is a genuinely useful data point, thank you. Glucose dependence is the single most consequential fact in the article for a general reader and it is currently three sentences deep in a definition list. — — Hedgerow_Hal (talk) 09:44, 3 April 2026 (UTC)

Is the "50–75% degraded before leaving the gut" figure attributable?No consensus

§Inactivation and clearance gives 50–75% pre-hepatic degradation, sourced to the 2018 review. The review states the figure but attributes it onward to earlier hepatic-extraction work. Per Project:Verifiability we should either cite the underlying study or attribute the range in-text as a review estimate. — — CitationChaser (talk) 16:20, 19 November 2025 (UTC)

In-text attribution is the cheaper fix and is arguably more honest, since the underlying estimates vary by method. No objection to either. — — Chromatokid (talk) 07:55, 20 November 2025 (UTC)

Requested move: → GLP-1Requested move

Requested move. A move of this page has been proposed below. The question is whether the proposed title is the one a reader would most plausibly search for, per Project:Manual of style.

Requested move. Propose moving this article to GLP-1 as the common name. Search traffic for the abbreviation dwarfs the expanded form and readers will type the short form. — — MoveRequestMio (talk) 12:03, 22 January 2026 (UTC)

Oppose. The abbreviation is ambiguous in exactly the way that hurts a reference work: on this wiki "GLP-1" is used colloquially to mean the drug class, not the hormone. Keeping the expanded title and letting GLP-1 receptor agonist carry the class is the clearer arrangement. A redirect from the abbreviation already exists. — — NPOV_Nadia (talk) 13:48, 22 January 2026 (UTC)

Oppose per Nadia. Also note the hyphenation would then need settling — GLP-1 versus GLP1 — and the primary literature is not consistent. — — INN_Ingrid (talk) 09:11, 23 January 2026 (UTC)

Closing as not moved, no consensus to move and a clear disambiguation argument against. — — Ref_Desk_Ron (talk) 11:37, 26 January 2026 (UTC)

This page was last edited on 3 April 2026, by Hedgerow_Hal. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).